Shots:
Prelude Therapeutics entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722, an oral selective KAT6A degrader, in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo) in pts. with HR+/HER2- breast cancer
The combination cohorts are part of Prelude’s P-I study, supported by preclinical data demonstrating synergy between PRT13722, CDK4/6 inhibitors,…
